The evolving therapeutic landscape of PCSK9 inhibition - PubMed
6 days ago
- #LDL cholesterol
- #PCSK9 inhibition
- #Cardiovascular disease
- Cardiovascular disease is the leading cause of death globally, with LDL as a major modifiable risk factor.
- PCSK9 regulates LDL receptor expression; loss-of-function variants lead to lower LDL-C and reduced ASCVD risk.
- PCSK9-targeted therapies are developed for hypercholesterolemia, especially for statin-intolerant or familial hypercholesterolemia patients.
- Therapies have evolved from monoclonal antibodies to siRNA, oral treatments, and gene editing for permanent PCSK9 inhibition.
- The review covers approved PCSK9 inhibitors, novel therapies in development, and expanding indications for PCSK9 inhibition.